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Epithelial-mesenchymal interactions mediated by soluble growth factors determine the evolution of vertebrate lung physiology,
including development, homeostasis, and repair. The final common pathway for all of these positively adaptive properties of the
lung is the expression of epithelial parathyroid-hormone-related protein, and its binding to its receptor on the mesenchyme,
inducing PPARγ expression by lipofibroblasts. Lipofibroblasts then produce leptin, which binds to alveolar type II cells, stimulating
their production of surfactant, which is necessary for both evolutionary and physiologic adaptation to atmospheric oxygen from
fish toman. A wide variety of molecular insults disrupt such highly evolved physiologic cell-cell interactions, ranging from overdis-
tention to oxidants, infection, and nicotine, all of which predictably cause loss of mesenchymal peroxisome-proliferator-activated
receptor gamma (PPARγ) expression and the transdifferentiation of lipofibroblasts to myofibroblasts, the signature cell type for
lung fibrosis. By exploiting such deep cell-molecular functional homologies as targets for leveraging lung homeostasis, we have
discovered that we can effectively prevent and/or reverse the deleterious effects of these pathogenic agents, demonstrating the
utility of evolutionary biology for the prevention and treatment of chronic lung disease. By understanding mechanisms of health
and disease as an evolutionary continuum rather than as dissociated processes, we can evolve predictive medicine.
“Those who cannot remember the past are condemned to repeat it.” George Santayana
1. Background
Normal lung development is the result of a functionally
interconnected series of cell-molecular steps. This sequence
of biologic events has been positively selected for evolution-
arily over biologic time and space [1], resulting in optimal
gas exchange mediated by alveolar homeostasis [2]. Else-
where we have suggested that chronic lung disease (CLD)
causes simplification of the lung in a manner consistent with
the reversal of the evolutionary process [3, 4]. Therefore,
by identifying those mechanisms that have evolved under
selection pressure for optimal gas exchange [5], we have the-
orized that we can effectively reverse the deleterious effects
of CLD by promoting the evolutionarily adaptive mecha-
nism [6], rather than by just treating the symptoms [7]. By
determining the cell-molecular sequence of spatiotemporal
signals that have evolved the lung over phylogeny and
ontogeny, we can identify physiologically rational targets for
effectively preventing and reversing the deleterious effects
of endogenous and exogenous factors known to irreversibly
damage normal lung development and function.
The ground-breaking tissue culture experiments con-
ducted by Grobstein in 1967 demonstrating that lung
development was dependent on endodermal-mesenchymal
interactions [8] led to decades of research to determine
the underlying cell-molecular mechanisms. The seemingly
simple epithelial-mesenchymal interactions during well-
defined (embryonic, pseudoglandular, canalicular, saccular,
and alveolar), but overlapping stages of lung development
result in more than 40 different cell types [9]. Much of what
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we currently know about the mechanisms involved in lung
development is derived from such studies of cultured lung
cells signaling through growth factor-mediated pathways for
proliferation and differentiation [10–12]. The discovery that
epithelial-mesenchymal signaling induced the lipofibrob-
last via peroxisome proliferator-activated receptor gamma
(PPARγ) [13] gave rise to the hypothesis that normal lung
development could be reconstituted [14] and recapitulated
[15, 16]. The following recounts the essential role of PPARγ
in lipofibroblast differentiation and its exploitation for the
effective treatment of the preterm lung.
2. Epithelial-Mesenchymal Interactions
Generate Alveolar Lung Development
The paracrine growth factor model used to study the matu-
ration of the pulmonary surfactant system and the etiology
of CLD is shown in the accompanying schematic (see
Figure 1, steps 1–11). Briefly, we have observed coordinating
effects of stretch on alveolar type II (ATII) cell expres-
sion of parathyroid-hormone-related protein (PTHrP) and
PGE2 (Prostaglandin E2) (step 1), the lipofibroblast PTHrP
receptor (step 2), PPARγ upregulation (step 4) via Protein
Kinase A activation (step 3), its downstream effect on lipofi-
broblast ADRP (Adipocyte-Differentiation-Related Protein)
expression (step 5) and triglyceride (TG) uptake by both the
lipofibroblast and the ATII cell (steps 6a and 6b), and on the
interaction between lipofibroblast-produced leptin (step 7)
and the ATII cell leptin receptor (step 8), stimulating de
novo surfactant phospholipid synthesis by ATII cells (step 9).
The schematic depicts lipofibroblast-to-myofibroblast trans-
differentiation (step 10) due to decreased PTHrP following
exposure to hyperoxia, volutrauma, or infection. All of these
effects are shown to be prevented by PPARγ agonists (step 11).
These studies were originally fostered by Barry Smith’s
seminal observation [10] that glucocorticoids accelerate ATII
cell surfactant synthesis by stimulating fibroblast synthesis
of an oligopeptide that he termed Fibroblast-Pneumonocyte
Factor (FPF). It was known at that time that lung, prostate,
and mammary mesodermal development were under endo-
crine control. Importantly, it was shown that early signals
emanated from the epithelium to differentiate the immature
mesenchyme in the neighboring epithelium of the devel-
oping mammary gland [17]. Moreover, Brody’s laboratory
had shown that the developing lung fibroblast acquired an
adipocyte-like phenotype [18–20], termed the lipid-laden
fibroblast, leaving open the question as to whether these cells
might be a source of lipid substrate for surfactant synthesis
by the ATII cell. The Torday laboratory later discovered the
physiologic significance of these lipid-laden fibroblasts by
coculturing them with type II cells, which resulted in the
rapid trafficking of the lipid from the fibroblast to the type
II cell, and its highly enriched incorporation into specific
surfactant phospholipids. These data indicated the existence
of a specific mechanism for the recruitment of lipid substrate
from the vasculature to the type II cell for de novo surfactant
synthesis. This trafficking was even more robust when the
cocultured cells were treated with glucocorticoids, which
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Figure 1: Schematic for paracrine determinants of alveolar home-
ostasis and disease.
are known to stimulate cell-cell interactions in the alveolus
in association with increased surfactant synthesis, further
reinforcing the notion of a putative mechanism for neutral
lipid trafficking for surfactant synthesis since it appeared to
be a regulated process [21].
Interestingly, the fibroblasts took up the neutral lipid, but
did not release it unless they were in the presence of type II
cells; conversely, the type II cells were unable to take up neu-
tral lipid. These observations led to the discovery that type II
cell secretion of prostaglandin E2 (Figure 1, step 1), a stretch-
and glucocorticoid-regulated mechanism, caused the active
release of neutral lipid from the fibroblasts [22]. This effect
was further stimulated by glucocorticoid treatment of the
lung fibroblasts [22], but the nature of the lipid uptakemech-
anism by the type II cells remained unknown. Yet we were
well aware that the synthesis of pulmonary surfactant was a
so-called “on demand” system [23–25], in which increased
alveolar distension resulted in increased surfactant produc-
tion, suggesting the existence of a stretch-sensitive signal
emanating from the type II cell. With this in mind, we began
studying the role of PTHrP in lung development because
(a) it was expressed in the embryonic endoderm [26], (b)
its receptor was present on the adepithelial mesoderm [27],
(c) it had been shown to be stretch regulated in the urinary
bladder [28] and uterus [29], and distension of the lung was
known to be of physiologic importance in normal lung devel-
opment [30], (d) knockout of PTHrP caused stage-specific
inhibition of fetal lung alveolarization in the transition from
the pseudoglandular to the canalicular stage [31].
Early functional studies of PTHrP had shown that it was a
paracrine factor that stimulated surfactant phospholipid syn-
thesis [32], and that it was stretch regulated [11] (Figure 1,
step 1). We subsequently discovered that PTHrP stimulated
neutral lipid uptake by developing lung fibroblasts (Figure 1,
steps 1 and 2), which we chose to call lipofibroblasts [33], by
upregulating ADRP (Figure 1, step 2), a molecule previously
shown to be necessary for lipid uptake and storage [34]
(Figure 1, step 5). We subsequently found that ADRP was the
factor necessary for the uptake of neutral lipid by the lipofi-
broblast (Figure 1, step 6a) and transit of neutral lipid from
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the lipofibroblast to the ATII cell for surfactant phospholipid
synthesis (Figure 1, step 6b) [35, 36]. Themissing component
for the PTHrP regulation of lung surfactant was the putative
lipofibroblast paracrine factor that empirically stimulated
ATII cell surfactant synthesis (32). Reasoning that lipofi-
broblasts were homologs of adipocytes, we hypothesized that
lipofibroblasts, like fat cells, expressed leptin, which would
bind to the type II cell and stimulate surfactant synthesis—
we found that lipofibroblasts did indeed express leptin
during rat lung development, plateauing immediately prior
to the onset of surfactant synthesis by the type II cell, and that
leptin stimulates ATII cell surfactant synthesis [37] (Figure 1,
step 7). Importantly, from a mechanistic standpoint, we
discovered that type II cells express the leptin receptor [38]
(Figure 1, step 8), thus providing a ligand-receptor signaling
pathway between the lipofibroblast and type II cell. More-
over, PTHrP was discovered to stimulate leptin expression
by fetal lung fibroblasts [37] (Figure 1, steps 1, 2 and 7),
thus providing an integrated, growth factor-mediated home-
ostatic paracrine loop for the synthesis of pulmonary
surfactant, as predicted by the PTHrP-based model of lung
development.
Since the major inducers of bronchopulmonary dysplasia
(BPD)—barotrauma [39], oxotrauma [40] and infection
[41] —all cause ATII cell injury and damage, we investigated
the effects of PTHrP deprivation on the lipofibroblast
phenotype, only to discover that in the absence of PTHrP, the
lipofibroblast transdifferentiates to a myofibroblast, the cell-
type that characterizes lung fibrosis. Furthermore, myofi-
broblasts cannot support type II cell growth or differenti-
ation, whereas lipofibroblasts can [13], demonstrating the
functional significance of these two fibroblast phenotypes
for lung development; importantly, when myofibroblasts
are treated with a PPARγ agonist, they revert back to the
lipofibroblast phenotype, including their ability to promote
type II cell growth and differentiation. As a result of these
seminal observations, we have found that all of the above-
mentioned BPD inducers cause downregulation of alveolar
li-pofibroblast PPARγ expression [38, 42, 43], inhibiting nor-
mal lung development. Moreover, in all of these conditions,
PPARγ agonists have been found to prevent delayed lung
development, and in the case of nicotine inhibition of lung
development, to even reverse this process [42–51].
3. The Evolution of Peroxisome Biology
Peroxisomes were first observed by Rhodin in 1954 [52] and
were characterized as a novel cellular organelle by de Duve
and Baudhin, whose laboratory first isolated peroxisomes
from rat liver and determined their biochemical properties
[53]. Since the core mechanisms involved in peroxisome
biology are shared by a wide variety of organisms, it sug-
gests a common evolutionary origin. Speculations about the
evolution of peroxisomes began shortly after their discov-
ery. Early photomicrographs suggested interactions between
the peroxisome and endoplasmic reticulum (ER), leading
some to speculate that peroxisomes were derived from the
endomembrane system [54]. Subsequently, an alternative
view that peroxisomes are independent organelles originat-
ing by endosymbiosis was proposed after it was observed that
the peroxisomes formed from the division of existing per-
oxisomes, and that they import proteins [55], both features
resembling those of bacterially derived organelles such as
mitochondria and chloroplasts. But the most elaborate
hypothesis regarding the evolutionary origins of the perox-
isome was that of de Duve [56], who proposed a metabolic
scenario for the establishment of an endosymbiosis mech-
anism that entailed the role of peroxisome enzymes in the
detoxification of highly reactive oxygen species. In this sce-
nario, the protoperoxisome was acquired at a time when the
level of atmospheric oxygen was increasing and represented
a toxic compound for the majority of living organisms.
This concept is consistent with the evolution of the lung
lipofibroblast [15] as an example of how vertebrates have
entrained otherwise toxic substances in the environment as
physiologic mechanisms [57]. Csete et al. [58] have observed
that skeletal muscle satellite cells in culture will sponta-
neously become adipocytes in 21% oxygen, but not in 6%
oxygen, suggesting that the episodic increases and falls in
atmospheric oxygen over the last 500 million years may have
caused the evolution of fat cells in the lung (lipofibroblasts)
and periphery (adipocytes) [3]. Such a mechanism is a selec-
tion advantage since the lipofibroblast protects the alveolus
against oxidant injury [59], and its production of leptin
[37, 38] may have fostered modern-day stretch-regulation of
alveolar surfactant [60–63], facilitating the increase in lung
surface area [1, 4, 15] and mediating ventilation-perfusion
matching [64]. The concomitant production of oxygen free
radicals, lipid peroxides and other oxidative products likely
generated eicosanoids (22) as a balancing selection for
endogenous PPAR ligands. Bolstered by the popularity of the
serial endosymbiotic theory [65], this view has been the most
widely accepted among biologists.
More recently, the endosymbiosis theory for the origin of
the peroxisome has been challenged. Experimental evidence
shows a close relationship between the ER and peroxisome
formation-certain peroxisomal membrane proteins must
first be targeted to the ER before they reach the peroxisome
[66], and peroxisome-less mutant yeast can form new peroxi-
somes from the ER upon introduction of the wild-type
peroxisome gene [67]. And independent evidence for an
evolutionary link between peroxisomes and the ER was pro-
vided by phylogenetic studies showing that homologous rela-
tionships between components of the peroxisomal import
machinery and those of the ER-decay (ERAD) pathway [68,
69]. These data have led the research community to conclude
that the peroxisome originates in the ER [70, 71], but have
not excluded the possibility of an endosymbiont [71].
In the early 1990s,based on sequence homology with
previously identified members of nuclear hormone receptor
superfamily, three PPAR isotypes (PPARα, β/δ, and γ) were
identified, initially in Xenopus laevis and the mouse, and
later in human, rat, fish, hamster, and chicken [72, 73]. These
isotypes were initially shown to be activated by peroxisome
proliferators, a group of substances able to induce peroxi-
some proliferation. Subsequently, various endogenous and
exogenous PPAR ligands were identified, including fatty
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acids, eicosanoids, synthetic hypolipidemic, and antidiabetic
agents [74]. Though PPARs are involved in several aspects of
rodent development, they are most importantly involved in
various aspects of lipid metabolism and energy homeostasis,
with PPARγ’s role in adipogenesis and lipid storage and
PPARα’s role in fatty acid catabolism in the liver being the
best characterized [74, 75].
4. PPARγ Mediates the Evolutionary History of
the Adipocyte: Homologies Run Deep
Over the course of vertebrate evolution, during the Phanero-
zoic Period (the last 500 million years) the amount of oxygen
in the atmosphere has increased to its current level of 21%.
However, it did not increase linearly; instead, it increased and
decreased several times, reaching concentrations as high as
35% and falling to as low as 15% over this time-period [76].
As pointed out above, the increased oxygen tension may
have caused the differentiation of muscle satellite cells into
lipofibroblasts, or lung adipocytes, in the lung, as the first
directly affected anatomic site where the increased atmo-
spheric oxygen would have generated selection pressure
for evolutionary change. Consistent with this hypothesized
adaptive response to the rising oxygen tension in the atmo-
sphere, we have previously shown that the lipids stored
in alveolar lipofibroblasts protect the lung against oxidant
injury [59]. Like adipocytes, lipofibroblast differentiation
requires upregulation of PPARγ [13, 42, 44], which stimu-
lates differentiation of myofibroblasts to lipofibroblasts [45].
In turn, the leptin secreted by the lipofibroblasts binds to
its receptor on the alveolar epithelial cells lining the alveoli,
stimulating surfactant synthesis [37, 38], and reducing alve-
olar surface tension. This results in a more deformable and
efficient gas-exchange surface. Such positive selection pres-
sure could have led to the stretch-regulated coregulation of
surfactant and microvascular perfusion [77] by PTHrP,
recognized physiologically as the mechanism of ventilation-
perfusion matching. The evolution of these molecular mech-
anisms could ultimately have given rise to the definitive
mammalian lung alveolus, with maximal gas exchange
resulting from coordinate stretch-regulated surfactant pro-
duction and alveolar capillary perfusion, thinner alveolar
walls due to PTHrP’s apoptotic or “programmed cell death”
effect on fibroblasts [78], and a blood-gas barrier buttressed
by type IV collagen [79]. We speculate that this last feature
may have contributed generally to the molecular bauplan
for the peripheral microvasculature of evolving vertebrates,
given its effect on angiogenesis [80]. One physiologic conse-
quence of the increased oxygenation may have been the con-
comitant induction of fat cells in the peripheral circulation,
which led to endothermy or warm bloodedness- Mezentseva
et al. [81] have shown that thermogenic fat cells differentiate
from embryonic limb bud mesenchymal cells in association
with the expression of PPARγ. The resulting increase in body
temperature synergized increased lung oxygenation because
lung surfactant is 300% more active at 37◦C than at ambient
atmospheric temperature (i.e., the body temperature for
cold-blooded organisms). For example, map turtles (Grapte-
mys geographica) show different surfactant compositions
depending on the ambient temperature [82]. Therefore, the
advent of thermogenesis would have facilitated the physical
increase in lung surfactant surface-tension-lowering activity.
Moreover, it has been shown that treatment of cold blooded
lizards with leptin, a product of adipocytes, increases their
body temperature [83]. These synergistic selection pressures
for adipogenesis would have been further functionally
enhanced by the coordinate physiologic effects of epineph-
rine on the heart [84], lung [85], and fat depots [86], under-
pinned structurally by the increased production of leptin
by fat cells, which is known to promote the formation of
blood vessels [80] and bone [87], accommodating the infra-
structural changes necessitated by the evolution of complex
physiologic traits.
5. Everything Put Together Falls Apart in
Bronchopulmonary Dysplasia
Since BPD can be induced by all of the varied factors cited
above, disrupting epithelial-mesenchymal interactions, we
designed experiments to determine the spatiotemporal
effects of these disruptors on PTHrP-PPARγ signaling. The
effective distension of the newborn lung has a profound
physiologic effect on pulmonary homeostasis [60, 61], and
stretching of the ATII cell increases the expression and
production of PTHrP [11]. In contrast, overdistension of the
type II cell [88] results in downregulation of PTHrP expres-
sion, and hence PPARγ, simulating the consequences of
volutrauma [43]. Since hyperoxia also augments the transdif-
ferentiation of lipofibroblasts to myofibroblasts in vitro [44],
we determined the occurrence of hyperoxia-induced alveolar
lipo-to-myofibroblast transdifferentiation in vivo. Either 24
hour or 7d in vivo exposure to hyperoxia significantly
decreased the expression of lipogenic markers, and signifi-
cantly increased the myogenic markers in association with
arrested alveolarization; the lungs demonstrated relatively
larger air spaces, thinned interstitia, decreased secondary
septal crest formation, and a significant reduction in radial
alveolar counts. Moreover, since lung inflammation is a key
factor predisposing preterm infants to BPD, we determined
the effects of lipopolysaccharide (LPS) on key alveolar epi-
thelial-mesenchymal paracrine interactions [46]. There were
acute (24 hour), significant increases in the expression of
PTHrP, PPARγ, ADRP, and surfactant protein-B (SP-B),
without any significant effects on the expression of α-smooth
muscle actin (αSMA). This was followed (72 h) by significant
decreases in the expression of PTHrP, PPARγ, ADRP, and SP-
B, accompanied by a significant increase in the expression of
αSMA, the key molecular and functional marker for BPD.
And since nicotine affects lung growth and development
[47], we determined the effect of in utero nicotine exposure
on epithelial-mesenchymal interactions as well. Nicotine
indirectly inhibited ATII cell proliferation and metabolism
via its paracrine effects on the adepithelial lipofibroblasts
[48], causing lipo-to-myofibroblast transdifferentiation [49,
89]. In all of the above-cited studies, a PPARγ agonist blocked
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the disruptive effects, even reversing them in the case of
nicotine.
6. PPARγ Agonists Turn on a “Master
Switch” for Normal Lung Development
That Universally Prevents BPD
It is clear from the work outlined above that lipofibroblast
PPARγ signaling plays a central role in epithelial-mesen-
chymal interactions by maintaining alveolar homeostasis in
volutrauma, oxotrauma, infection, and nicotine-mediated
lung injury. The lipofibroblast expresses PPARγ in response
to PTHrP signaling from the ATII cell, resulting in both the
direct protection of the mesoderm against oxidant injury
[59], and protection against atelectasis by augmenting sur-
factant protein [37] and phospholipid [38] synthesis. Molec-
ular injury to either the ATII cell or the lipofibroblast
downregulates this molecular signaling pathway, causing
myofibroblast transdifferentiation. And as indicated above,
myofibroblasts cannot promote ATII cell proliferation and
differentiation [13], leading to the failed alveolarization
characteristic of BPD [50]. In contrast, lipofibroblasts sup-
port ATII cell proliferation and differentiation under the
influence of factors implicated in the pathogenesis of BPD.
This scenario is validated by a plethora of in vitro [13, 44–46,
51, 89, 90] and in vivo [42, 43, 48, 89] studies. Importantly,
these studies show that PPARγ agonists such as Prostaglandin
J2 and rosiglitazone can prevent or reverse myofibroblast
transdifferentiation, potentially preventing the inhibition of
alveolarization in the developing lung, the hallmark of CLD
of the newborn [13, 42, 45, 47–49, 51, 89, 90].
7. Conclusion
Using a basic cell biologic approach to elucidate the patho-
physiology of BPD based on evolved cell-physiologic princi-
ples, we have determined the paracrine cell/molecular mech-
anism by which stretch coordinates epithelial-mesenchymal
signaling, upregulating key genes for the induction of
the prohomeostatic lipofibroblast phenotype—including
PPARγ, ADRP, and leptin—and the retrograde stimulation
of ATII cell surfactant phospholipid and protein synthesis
by the lipofibroblast product leptin. Each of these paracrine
interactions requires cell-specific receptors on adjacent cells
derived from the endoderm or mesoderm, respectively, that
is, PTHrP receptors on themesoderm and leptin receptors on
the endoderm, to specifically mediate the signaling pathways
within each cell type. More importantly, we have exploited
the cell-specific molecular nature of this mechanism in order
to effectively and comprehensively prevent and treat lung
injuries that affect this signaling pathway. By identifying
deep homologous mechanisms that have determined both
the phylogeny and ontogeny of the lung, by using exogenous
PPARγ agonists we have been able to prevent and even
reverse the effects of a wide variety of injurious agents
affecting the epithelial-mesenchymal interactions that have
evolved to determine the gas-exchange surface of the lung
[1–5].
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